The news follows the SPAC’s eight consecutive adjournments of the completion vote. However, during this period, Priveterra managed to secure up to $105 million in new funding through a mix of facilities.
Of this, $20 million is to follow the terms of the deal’s existing A-1 notes, joining $20 million in investments made by existing AEON investors at $7 per share. A new investor ACM ASOF VIII has also agreed to purchase 1,000,000 shares for $7 per share and will be further compensated with 75,000 newly issued shares.
Importantly, this $47 million in note financing was enough to cover the transaction’s $40 million minimum cash condition.
The resulting combined company changed its name to AEON Biopharma, Inc. and is expected to commence trading of its shares of common stock and warrants on the NYSE under the ticker symbols “AEON” and “AEON WS,” respectively, on July 24.
Priveterra inked its $201.8 million business combination with drug developer AEON on December 13. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
Mr. Robert Palmisano, Chairman and CEO of Priveterra, will join the new 5-member board to serve as a Director.